CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
Crispr Therapeutics Is Maintained at Buy by Needham
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks
RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
Crispr Therapeutics AG (CRSP) Gets a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: BioAtla (BCAB), Relay Therapeutics (RLAY) and Crispr Therapeutics AG (CRSP)
Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $82
CRISPR Therapeutics Analyst Ratings
Wells Fargo Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $65
We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Crispr Therapeutics Upgraded to Buy From Hold at Clear Street
Crispr Therapeutics AG: Balancing Growth Potential With Profitability Challenges – Hold Rating
Chardan Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $82
CRISPR Therapeutics Q1 EPS $(1.58) Misses $(1.21) Estimate, Sales $865.00K Miss $6.50M Estimate
Earnings Flash (CRSP) CRISPR Therapeutics AG Posts Q1 Revenue $865,000
CRISPR Therapeutics | 10-Q: Quarterly report
Crispr Therapeutics: Initial CTX310 Phase 1 Clinical Data Demonstrates Dose-Dependent Decreases in TG and LDL >CRSP